Gastrointestinal hormones stimulate growth of Foregut Neuroendocrine Tumors by transactivating the EGF receptor

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1833, Issue 3, 2013, Pages 573-582

  Di Florio, Alessia ^a   Sancho, Veronica ^a   Moreno, Paola ^a   Fave, Gianfranco Delle ^b   Jensen, Robert T ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cell growth; Gastrointestinal hormones; Neuroendocrine tumors; Pancreatic endocrine tumors; Transactivation

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GASTROINTESTINAL HORMONE; MATRIX METALLOPROTEINASE; NEUROTRANSMITTER; PROTEIN KINASE C; PROTEIN KINASE P60; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR ALPHA; TYROSINE;

ARTICLE; CANCER CELL; CELL ACTIVATION; CELL GROWTH; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; FOREGUT NEUROENDOCRINE TUMOR; HUMAN; HUMAN CELL; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SOMATOSTATINOMA; TUMOR GROWTH;

RATTUS;

EID: 84871897126     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2012.11.021     Document Type: Article

References (57)

1. Jensen R.T., Delle Fave G. Promising advances in the treatment of malignant pancreatic endocrine tumors. N. Engl. J. Med. 2011, 364:564-565.
2. Schimmack S., Svejda B., Lawrence B., Kidd M., Modlin I.M. The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbecks Arch. Surg. 2011, 396:273-298.
3. Capurso G., Fazio N., Festa S., Panzuto F., de Braud F., Delle Fave G. Molecular target therapy for gastroenteropancreatic endocrine tumours: biological rationale and clinical perspectives. Crit. Rev. Oncol. Hematol. 2009, 72:110-124.
4. Metz D.C., Jensen R.T. Gastrointestinal neuroendocrine tumors:; Pancreatic endocrine tumors. Gastroenterology 2008, 135:1469-1492.
5. Ito T., Igarashi H., Jensen R.T. Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J. Gastroenterol. 2012, 47:941-960.
6. Kulke M.H., Scherubl H. Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors. Gastrointest. Cancer Res. 2009, 3:S62-S66.
7. Hopfner M., Schuppan D., Scherubl H. Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives. World J. Gastroenterol. 2008, 14:2461-2473.
8. Schally A.V. New approaches to the therapy of various tumors based on peptide analogues. Horm. Metab. Res. 2008, 40:315-322.
9. Welin S., Fjallskog M.L., Saras J., Eriksson B., Janson E.T. Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors. Neuroendocrinology 2006, 84:42-48.
10. Papouchado B., Erickson L.A., Rohlinger A.L., Hobday T.J., Erlichman C., Ames M.M., Lloyd R.V. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod. Pathol. 2005, 18:1329-1335.
11. Hopfner M., Sutter A.P., Gerst B., Zeitz M., Scherubl H. A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839). Br. J. Cancer 2003, 89:1766-1775.
12. Wulbrand U., Wied M., Zofel P., Goke B., Arnold R., Fehmann H. Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. Eur. J. Clin. Invest. 1998, 28:1038-1049.
13. Siddique Z.L., Drozdov I., Floch J., Gustafsson B.I., Stunes K., Pfragner R., Kidd M., Modlin I.M. KRJ-I and BON cell lines: defining an appropriate enterochromaffin cell neuroendocrine tumor model. Neuroendocrinology 2009, 89:458-470.
14. Townsend C.M., Ishizuka J., Thompson J.C. Studies of growth regulation in a neuroendocrine cell line. Acta Oncol. 1993, 32:125-130.
15. Bhola N.E., Grandis J.R. Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front. Biosci. 2008, 13:1857-1865.
16. Liebmann C. EGF receptor activation by GPCRs: an universal pathway reveals different versions. Mol. Cell. Endocrinol. 2011, 331:222-231.
17. Moody T.W., Osefo N., Nuche-Berenguer B., Ridnour L., Wink D., Jensen R.T. Pituitary adenylate cyclase activating polypeptide causes tyrosine phosphorylation on the EGF receptor in lung cancer cells. J. Pharmacol. Exp. Ther. 2012, 341:873-881.
18. Majumdar I.D., Weber H.C. Biology of mammalian bombesin-like peptides and their receptors. Curr. Opin. Endocrinol. Diabetes Obes. 2011, 18:68-74.
19. Moody T.W., Berna M.J., Mantey S., Sancho V., Ridnour L., Wink D.A., Chan D., Giaccone G., Jensen R.T. Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells. Eur. J. Pharmacol. 2010, 637:38-45.
20. Liu X., Carlisle D.L., Swick M.C., Gaither-Davis A., Grandis J.R., Siegfried J.M. Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib. Exp. Cell Res. 2007, 313:1361-1372.
21. Moody T.W., Sancho V., Di Florio A., Nuche-Berenguer B., Mantey S., Jensen R.T. Bombesin receptor subtype-3 agonists stimulate the growth of lung cancer cells and increase EGF receptor tyrosine phosphorylation. Peptides 2011, 32:1677-1684.
22. Lui V.W., Thomas S.M., Wentzel A.M., Siegfried J.M., Li J.Y., Grandis J.R. Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. Oncogene 2003, 22:6183-6193.
23. Amorino G.P., Deeble P.D., Parsons S.J. Neurotensin stimulates mitogenesis of prostate cancer cells through a novel c-Src/Stat5b pathway. Oncogene 2007, 26:745-756.
24. Peghini P.L., Iwamoto M., Raffeld M., Chen Y.-J., Goebel S.U., Serrano J., Jensen R.T. Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Clin. Cancer Res. 2002, 8:2273-2285.
25. Rojas M., Yao S., Lin Y.Z. Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor. J. Biol. Chem. 1996, 271:27456-27461.
26. Li Y., Levesque L.O., Anand-Srivastava M.B. Epidermal growth factor receptor transactivation by endogenous vasoactive peptides contributes to hyperproliferation of vascular smooth muscle cells of SHR. Am. J. Physiol. Heart Circ. Physiol. 2010, 299:H1959-H1967.
27. Nilsson O., Wangberg B., McRae A., Dahlstrom A., Ahlman H. Growth factors and carcinoid tumours. Acta Oncol. 1993, 32:115-124.
28. Chaudhry A., Funa K., Oberg K. Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncol. 1993, 32:107-114.
29. Shah T., Hochhauser D., Frow R., Quaglia A., Dhillon A.P., Caplin M.E. Epidermal growth factor receptor expression and activation in neuroendocrine tumours. J. Neuroendocrinol. 2006, 18:355-360.
30. Kuntz E., Broca C., Komurasaki T., Kaltenbacher M.C., Gross R., Pinget M., Damge C. Effect of epiregulin on pancreatic beta cell growth and insulin secretion. Growth Factors 2005, 23:285-293.
31. Varkondi E., Pinter F., Robert K., Schwab R., Breza N., Orfi L., Keri G., Petak I. Biochemical assay-based selectivity profiling of clinically relevant kinase inhibitors on mutant forms of EGF receptor. J. Recept. Signal Transduct. Res. 2008, 28:295-306.
32. Zhang W., Bhola N., Kalyankrishna S., Gooding W., Hunt J., Seethala R., Grandis J.R., Siegfried J.M. Kinin b2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas. Mol. Cancer Res. 2008, 6:1946-1956.
33. Hinsley E.E., Hunt S., Hunter K.D., Whawell S.A., Lambert D.W. Endothelin-1 stimulates motility of head and neck squamous carcinoma cells by promoting stromal-epithelial interactions. Int. J. Cancer 2011, 130:40-47.
34. Kuiper P., Verspaget H.W., Biemond I., de Jonge-Muller E.S., Van Eeden S., Van Velthuysen M.L., Taal B.G., Lamers C.B. Expression and ligand binding of bombesin receptors in pulmonary and intestinal carcinoids The role of bombesin in carcinoids. J. Endocrinol. Invest. 2010, 34:665-670.
35. Bostwick D.G., Bensch K.G. Gastrin releasing peptide in human neuroendocrine tumours. J. Pathol. 1985, 147:237-244.
36. Reubi J.C. Peptide receptor expression in GEP-NET. Virchows Arch. 2007, 451(Suppl. 1):S47-S50.
37. Jensen R.T., Moody T.W. Bombesin-Related Peptides and Neurotensin: Effects on Cancer Growth/Proliferation and Cellular Signaling in Cancer. Handbook of Biologically active peptides 2006, 429-434. Elsevier, Amsterdam. A.J. Kastin (Ed.).
38. Germano P.M., Lieu S.N., Xue J., Cooke H.J., Christofi F.L., Lu Y., Pisegna J.R. PACAP induces signaling and stimulation of 5-hydroxytryptamine release and growth in neuroendocrine tumor cells. J. Mol. Neurosci. 2009, 39:391-401.
39. Leu F.P., Nandi M., Niu C. The effect of transforming growth factor beta on human neuroendocrine tumor BON cell proliferation and differentiation is mediated through somatostatin signaling. Mol. Cancer Res. 2008, 6:1029-1042.
40. Ishizuka J., Beauchamp R.D., Townsend C.M., Greeley G.H., Thompson J.C. Receptor-mediated autocrine growth-stimulatory effect of 5-hydroxytryptamine on cultured human pancreatic carcinoid cells. J. Cell. Physiol. 1992, 150:1-7.
41. Drozdov I., Kidd M., Gustafsson B.I., Svejda B., Joseph R., Pfragner R., Modlin I.M. Autoregulatory effects of serotonin on proliferation and signaling pathways in lung and small intestine neuroendocrine tumor cell lines. Cancer 2009, 115:4934-4945.
42. Kidd M., Siddique Z.L., Drozdov I., Gustafsson B.I., Camp R.L., Black J.W., Boyce M., Modlin I.M. The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development. Regul. Pept. 2010, 162:52-60.
43. Sun L., Morris L.M., Luo J., Mackey L.V., Leslie J.S., Franko-Tobin L.G., Fuselier J.A., Lepage K.T., Coy D.H. Application of human pancreatic carcinoid BON cells for receptor-targeted drug development. J. Drug Target. 2010, 19:719-730.
44. Shojamanesh H., Gibril F., Louie A., Ojeaburu J.V., Bashir S., Abou-Saif A., Jensen R.T. Prospective study of the anti-tumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinomas. Cancer 2002, 94:331-343.
45. Parekh D., Ishizuka J., Townsend C.M., Haber B., Beauchamp R.D., Karp G., Kim S.W., Rajaraman S., Greeley G., Thompson J.C. Characterization of a human pancreatic carcinoid in vitro: morphology, amine and peptide storage, and secretion. Pancreas 1994, 9:83-90.
46. Sun L., Luo J., Mackey L.V., Morris L.M., Franko-Tobin L.G., Lepage K.T., Coy D.H. Investigation of cancer cell lines for peptide receptor-targeted drug development. J. Drug Target. 2011, 19:719-730.
47. Hassan S., Dobner P.R., Carraway R.E. Involvement of MAP-kinase, PI3-kinase and EGF-receptor in the stimulatory effect of neurotensin on DNA synthesis in PC3 cells. Regul. Pept. 2004, 120:155-166.
48. Kisfalvi K., Guha S., Rozengurt E. Neurotensin and EGF induce synergistic stimulation of DNA synthesis by increasing the duration of ERK signaling in ductal pancreatic cancer cells. J. Cell. Physiol. 2005, 202:880-890.
49. Cheng S., Yuan C.G. Differential effect of galanin on proliferation of PC12 and B104 cells. Neuroreport 2007, 18:1379-1383.
50. Sturani E., Zippel R., Toschi L., Morello L., Comoglio P.M., Alberghina L. Kinetics and regulation of the tyrosine phosphorylation of epidermal growth factor receptor in intact A431 cells. Mol. Cell. Biol. 1988, 8:1345-1351.
51. Lee E., Yi J.Y., Chung E., Son Y. Transforming growth factorbeta(1) transactivates EGFR via an H(2)O(2)-dependent mechanism in squamous carcinoma cell line. Cancer Lett. 2010, 290:43-48.
52. Prenzel N., Zwick E., Daub H., Leserer M., Abraham R., Wallasch C., Ullrich A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999, 402:884-888.
53. Sue Y.M., Chen C.H., Hsu Y.H., Hou C.C., Cheng C.Y., Chen Y.C., Lin S.L., Chen T.W., Chen T.H. Urotensin II induces transactivation of the epidermal growth factor receptor via transient oxidation of SHP-2 in the rat renal tubular cell line NRK-52E. Growth Factors 2009, 27:155-162.
54. Mukhin Y.V., Garnovsky E.A., Ullian M.E., Garnovskaya M.N. Bradykinin B2 receptor activates extracellular signal-regulated protein kinase in mIMCD-3 cells via epidermal growth factor receptor transactivation. J. Pharmacol. Exp. Ther. 2003, 304:968-977.
55. Zhang Q., Bhola N.E., Lui V.W., Siwak D.R., Thomas S.M., Gubish C.T., Siegfried J.M., Mills G.B., Shin D., Grandis J.R. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol. Cancer Ther. 2007, 6:1414-1424.
56. Xiao D., Qu X., Weber H.C. Activation of extracellular signal-regulated kinase mediates bombesin-induced mitogenic responses in prostate cancer cells. Cell. Signal. 2003, 15:945-953.
57. Weber H.C. Regulation and signaling of human bombesin receptors and their biological effects. Curr. Opin. Endocrinol. Diabetes Obes. 2009, 16:66-71.